First Ascent Biomedical's technology represents a shift from a one-size-fits-all approach to a tailored strategy, offering hope to cancer patients who have exhausted traditional options. The company's functional precision medicine platform integrates drug testing, DNA/RNA sequencing and AI-guided tumor weakness mapping to test hundreds of FDA-approved drugs against a patient's unique cancer profile. The platform delivers a highly personalized, actionable plan to a patient's physician in an average of 10 days.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/13/25 | $6,000,000 |
TechStars Vidal Duart Enterprises | undisclosed |
